Mutational analysis of selected high-grade malignancies in a premenopausal gynecologic cancer population: a potential for targeted therapies?

Table 4 Sarcoma/Other Profile

n = 5					Genes associated with this histologic type^b
Age					BRCA2
Range	15–39				CTNNB1
Mean	25				EGFR
Median	24				FOXL2
BMI					c-KIT
Range	20–46.6				P16
Mean	31.6				TP53
Median	23
Survival
Range	15–867
Mean	259.6
Median	182
Cancer Type
Sarcoma	3		Ovary (1) Endometrial (2)
Germ Cell	1		Ovary (1)
HG Sex Cord	1		Ovary (1)
		Chemo	Rad	Alive	Novel Targets	Profiles
Location
Ovary	3	Plat/Etoposide (1) None (1) Unknown (1)	0	1 (33%)	MBD1 (1) ROS1 (3) EGFR (1) ERBB3 (1) KMT2D (1) NTRK1 (1)	MBD1, ROS1 (1) ROS1, EGFR (1)^a ROS1, ERBB3, KMT2D, NTRK1 (1)^a
Endometrial	2	Gemzar/Taxotere (1) None (1)	0	1 (50%)	CMPK1 (1) MBD1 (1) GPR124 (1)	CMPK1, MBD1 (1) GPR124 (1)^a

^aindicates these profiles are associated with negative outcomes in our cohort; ^bdata and sources retrieved from http://cancer.sanger.ac.uk/cosmic